Global Health Success Stories 2026

From new vaccine and financing commitments to disease elimination milestones, stronger outbreak response, and gains in child survival and laboratory systems, 2026 has already delivered several concrete signs of progress in global health. These examples show what is possible when political commitment, community engagement, strong public health systems, and international cooperation come together.

January 2026 | Trachoma burden falls below 100 million for the first time
A major neglected tropical disease milestone came at the start of the year, when WHO reported that the number of people requiring interventions against trachoma had fallen to 97.1 million as of November 2025, down from 1.5 billion in 2002. That is a 94% reduction, reflecting sustained country action and long-term implementation of the SAFE strategy. 

January 2026 | New financing for community health systems across Africa
The Global Fund announced new commitments to strengthen community health systems in Africa, including £3 million from Comic Relief UK, building on US$5 million from the Johnson & Johnson Foundation and US$6 million from the Skoll Foundation. Together, these commitments also unlocked US$14.9 million in matching funds from the Gates Foundation, reinforcing long-term investment in frontline health systems. 

January 2026 | Gavi expands innovation partnerships for immunisation and primary care
At Davos, Gavi announced a set of new partnerships aimed at moving proven health innovations to scale. Among the most concrete examples, Gavi, Grand Challenges Canada (GCC) and 500 Global aim to mobilise up to US$300 million for the Innovation Scale-Up Facility. In Ghana and Côte d’Ivoire, a new initiative linked to cocoa-farming communities is targeting 140,000 children in its first three years, with more than 600,000 people expected to benefit through stronger primary healthcare, cold-chain improvements, community health worker support, and digital health insurance enrolment. Gavi also expanded its Zipline partnership to reach zero-dose communities in Kaduna State, Nigeria by drone delivery. 

January 2026 | Ethiopia ends its first-ever Marburg outbreak
Ethiopia declared the end of its first Marburg virus disease outbreak after going 42 days without a new confirmed case. The outbreak resulted in 19 reported cases, while 857 contacts completed follow-up and around 3,800 samples were tested during the response. It is a strong example of rapid containment through surveillance, contact tracing, laboratory support, and coordinated emergency action.

January 2026 | Saudi Arabia pledges US$39 million to the Global Fund
Saudi Arabia pledged US$39 million to the Global Fund’s Eighth Replenishment for the 2026 to 2028 period. According to the Global Fund, the contribution will support HIV, tuberculosis and malaria programmes, alongside stronger health systems and community-based services in more than 100 countries. Saudi Arabia’s cumulative contributions now exceed US$200 million.

January 2026 | Ethiopia reaches more than 26 million children in a polio campaign
Ethiopia reported that its latest integrated polio campaign reached more than 26 million children. The campaign combined vaccination with additional services such as nutrition screening, surveillance, and identification of zero-dose and under-vaccinated children, showing the value of integrated delivery at scale.

January 2026 | Real-world malaria vaccine data show strong impact in three African countries
A 2026 peer-reviewed analysis from Ghana, Kenya, and Malawi found that the RTS,S malaria vaccine is associated with substantially lower rates of severe malaria and hospitalisation under routine use. Among nearly 39,500 children included in the analysis, the vaccine was linked with a 58% reduction in severe malaria and a 36% reduction in malaria-related hospitalisations, providing strong early evidence of impact under real-world conditions. 

February 2026 | WHO prequalifies an additional novel oral polio vaccine
WHO prequalified an additional novel oral polio vaccine type 2 (nOPV2), further strengthening the global vaccine supply used to respond to poliovirus type 2 outbreaks. The new product, manufactured by Biological E. Limited in India following technology transfer from PT Bio Farma in Indonesia, expands the quality-assured manufacturing base and supports a more resilient global outbreak response. 

February 2026 | Libya eliminates trachoma as a public health problem
WHO validated Libya’s elimination of trachoma as a public health problem, making it the 28th country worldwide to reach this milestone. The validation followed surveys and targeted follow-up work in the remaining affected area, confirming that prevalence had fallen below WHO thresholds. It is a major public health gain against one of the world’s leading infectious causes of blindness. 

February 2026 | Denmark becomes the first European Union country to eliminate mother-to-child transmission of HIV and syphilis
WHO certified Denmark for eliminating mother-to-child transmission of both HIV and syphilis. The achievement reflects years of maintaining at least 95% antenatal testing and treatment coverage and keeping new infant infections below the validation thresholds. WHO notes that routine testing and treatment reduced transmission to zero. 

March 2026 | Sudan declares an end to its cholera outbreak
After 48 days without a reported case, Sudan declared its cholera outbreak over. Across the outbreak period, vaccination efforts were said to have protected more than 23 million people. In a highly complex humanitarian setting, that marks an important public health achievement.

March 2026 | Chile becomes the first country in the Americas to eliminate leprosy disease
WHO verified Chile as the first country in the Americas to eliminate leprosy disease. The country had not detected a locally acquired case since 1993, and among the 47 cases reported between 2012 and 2023, none were locally acquired. It is a notable regional milestone for disease elimination and sustained surveillance. 

March 2026 | Malawi uses rapid vaccination to curb cholera risk
Malawi responded quickly to seasonal cholera risk with a five-day oral cholera vaccine campaign. Around 522,000 doses arrived in February, 410 health surveillance assistants were deployed, 1,350 health workers were trained, and the campaign surpassed its 95% coverage target in priority districts.

March 2026 | Malawi’s measles and rubella laboratory earns full WHO accreditation
Malawi’s national measles and rubella confirmation laboratory at Kamuzu Central Hospital achieved full WHO accreditation, scoring 94% on the general checklist and 84% on the serology checklist. The lab also achieved 100% accuracy in measles and rubella proficiency testing and exceeded the turnaround time target, strengthening outbreak detection and surveillance quality.

This page will be updated on a regular basis. We will continue tracking global health successes and milestones. 

Get Involved

Have a story to share? Get in touch at info[at]globalhealthhub.de